Primary chemotherapy in stage IIIA non-small cell lung cancer patients with clinically apparent mediastinal lymph node metastases: focus on five-year survivors

Mark G. Kris, Nael Martini, Richard J. Gralla, Katherine M W Pisters, Robert T. Heelan

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Stage IIIA non-small cell lung cancer patients with clinically apparent ipsilateral mediastinal lymph node metastases have an 18% resectability rate and a 3-year survival of 9% for resected patients. In an effort to improve these outcomes, we have treated 73 patients with chemotherapy prior to surgical exploration. All received 2-3 cycles of cisplatin (≥ 100 mg/m2), vindesine or vinblastine, and 84% received mitomycin (MVP). Radiotherapy was not given preoperatively. Major objective responses occurred in 77%. Overall, 79% were explored and 60% were completely resected. Pathologic complete responses were documented in 12%. Two additional cycles of chemotherapy were given postoperatively to resected patients. Patients with tumor in their resected mediastinal lymph nodes received mediastinal radiotherapy. The median survival for all patients was 19 months and the 5-year survival 16%. For completely resected patients, the median survival was 27 months and the 5-year survival 25%. Of the 42 patients who entered the trial 5 or more years ago, 8 survived at least 5 years. Six remain disease free and enjoy an excellent functional status. No chronic toxicity has occurred. For relapsed patients, most recurrences are systemic. Primary MVP chemotherapy produces high response rates and improves both resectability and survival. Further trials are underway to improve primary chemotherapy regimens and to identify methods to prevent systemic recurrence.

Original languageEnglish (US)
Pages (from-to)369-376
Number of pages8
JournalLung Cancer
Volume9
Issue number1-6
DOIs
StatePublished - 1993
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Survivors
Lymph Nodes
Neoplasm Metastasis
Drug Therapy
Survival
Radiotherapy
Vindesine
Recurrence
Vinblastine
Mitomycin
Cisplatin

Keywords

  • Chemotherapy
  • Combined modality therapy
  • Mediastinal invasion
  • Neoadjuvant chemotherapy
  • Non-small cell lung cancer
  • Preoperative chemotherapy
  • Stage IIIA disease
  • Surgery

ASJC Scopus subject areas

  • Oncology

Cite this

Primary chemotherapy in stage IIIA non-small cell lung cancer patients with clinically apparent mediastinal lymph node metastases : focus on five-year survivors. / Kris, Mark G.; Martini, Nael; Gralla, Richard J.; Pisters, Katherine M W; Heelan, Robert T.

In: Lung Cancer, Vol. 9, No. 1-6, 1993, p. 369-376.

Research output: Contribution to journalArticle

Kris, Mark G. ; Martini, Nael ; Gralla, Richard J. ; Pisters, Katherine M W ; Heelan, Robert T. / Primary chemotherapy in stage IIIA non-small cell lung cancer patients with clinically apparent mediastinal lymph node metastases : focus on five-year survivors. In: Lung Cancer. 1993 ; Vol. 9, No. 1-6. pp. 369-376.
@article{70177bf83c754a10890383e1292ce451,
title = "Primary chemotherapy in stage IIIA non-small cell lung cancer patients with clinically apparent mediastinal lymph node metastases: focus on five-year survivors",
abstract = "Stage IIIA non-small cell lung cancer patients with clinically apparent ipsilateral mediastinal lymph node metastases have an 18{\%} resectability rate and a 3-year survival of 9{\%} for resected patients. In an effort to improve these outcomes, we have treated 73 patients with chemotherapy prior to surgical exploration. All received 2-3 cycles of cisplatin (≥ 100 mg/m2), vindesine or vinblastine, and 84{\%} received mitomycin (MVP). Radiotherapy was not given preoperatively. Major objective responses occurred in 77{\%}. Overall, 79{\%} were explored and 60{\%} were completely resected. Pathologic complete responses were documented in 12{\%}. Two additional cycles of chemotherapy were given postoperatively to resected patients. Patients with tumor in their resected mediastinal lymph nodes received mediastinal radiotherapy. The median survival for all patients was 19 months and the 5-year survival 16{\%}. For completely resected patients, the median survival was 27 months and the 5-year survival 25{\%}. Of the 42 patients who entered the trial 5 or more years ago, 8 survived at least 5 years. Six remain disease free and enjoy an excellent functional status. No chronic toxicity has occurred. For relapsed patients, most recurrences are systemic. Primary MVP chemotherapy produces high response rates and improves both resectability and survival. Further trials are underway to improve primary chemotherapy regimens and to identify methods to prevent systemic recurrence.",
keywords = "Chemotherapy, Combined modality therapy, Mediastinal invasion, Neoadjuvant chemotherapy, Non-small cell lung cancer, Preoperative chemotherapy, Stage IIIA disease, Surgery",
author = "Kris, {Mark G.} and Nael Martini and Gralla, {Richard J.} and Pisters, {Katherine M W} and Heelan, {Robert T.}",
year = "1993",
doi = "10.1016/0169-5002(93)90693-R",
language = "English (US)",
volume = "9",
pages = "369--376",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "1-6",

}

TY - JOUR

T1 - Primary chemotherapy in stage IIIA non-small cell lung cancer patients with clinically apparent mediastinal lymph node metastases

T2 - focus on five-year survivors

AU - Kris, Mark G.

AU - Martini, Nael

AU - Gralla, Richard J.

AU - Pisters, Katherine M W

AU - Heelan, Robert T.

PY - 1993

Y1 - 1993

N2 - Stage IIIA non-small cell lung cancer patients with clinically apparent ipsilateral mediastinal lymph node metastases have an 18% resectability rate and a 3-year survival of 9% for resected patients. In an effort to improve these outcomes, we have treated 73 patients with chemotherapy prior to surgical exploration. All received 2-3 cycles of cisplatin (≥ 100 mg/m2), vindesine or vinblastine, and 84% received mitomycin (MVP). Radiotherapy was not given preoperatively. Major objective responses occurred in 77%. Overall, 79% were explored and 60% were completely resected. Pathologic complete responses were documented in 12%. Two additional cycles of chemotherapy were given postoperatively to resected patients. Patients with tumor in their resected mediastinal lymph nodes received mediastinal radiotherapy. The median survival for all patients was 19 months and the 5-year survival 16%. For completely resected patients, the median survival was 27 months and the 5-year survival 25%. Of the 42 patients who entered the trial 5 or more years ago, 8 survived at least 5 years. Six remain disease free and enjoy an excellent functional status. No chronic toxicity has occurred. For relapsed patients, most recurrences are systemic. Primary MVP chemotherapy produces high response rates and improves both resectability and survival. Further trials are underway to improve primary chemotherapy regimens and to identify methods to prevent systemic recurrence.

AB - Stage IIIA non-small cell lung cancer patients with clinically apparent ipsilateral mediastinal lymph node metastases have an 18% resectability rate and a 3-year survival of 9% for resected patients. In an effort to improve these outcomes, we have treated 73 patients with chemotherapy prior to surgical exploration. All received 2-3 cycles of cisplatin (≥ 100 mg/m2), vindesine or vinblastine, and 84% received mitomycin (MVP). Radiotherapy was not given preoperatively. Major objective responses occurred in 77%. Overall, 79% were explored and 60% were completely resected. Pathologic complete responses were documented in 12%. Two additional cycles of chemotherapy were given postoperatively to resected patients. Patients with tumor in their resected mediastinal lymph nodes received mediastinal radiotherapy. The median survival for all patients was 19 months and the 5-year survival 16%. For completely resected patients, the median survival was 27 months and the 5-year survival 25%. Of the 42 patients who entered the trial 5 or more years ago, 8 survived at least 5 years. Six remain disease free and enjoy an excellent functional status. No chronic toxicity has occurred. For relapsed patients, most recurrences are systemic. Primary MVP chemotherapy produces high response rates and improves both resectability and survival. Further trials are underway to improve primary chemotherapy regimens and to identify methods to prevent systemic recurrence.

KW - Chemotherapy

KW - Combined modality therapy

KW - Mediastinal invasion

KW - Neoadjuvant chemotherapy

KW - Non-small cell lung cancer

KW - Preoperative chemotherapy

KW - Stage IIIA disease

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=0027410808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027410808&partnerID=8YFLogxK

U2 - 10.1016/0169-5002(93)90693-R

DO - 10.1016/0169-5002(93)90693-R

M3 - Article

AN - SCOPUS:0027410808

VL - 9

SP - 369

EP - 376

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1-6

ER -